Feedback
Settings

Settings

Goto Application

393,093 results
Offices all Languages Stemming false Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:G01N33/48

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 39,310
1.WO/2021/009182PREDICTIVE DIAGNOSIS FOR THE PRESENCE OF DIABETES AND ALTERED GLUCOSE TOLERANCE
WO - 21.01.2021
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/EP2020/069915 Applicant GEK S.R.L. Inventor SPECIANI, Attilio Francesco
The present invention relates to a method for determining the propensity for development of diabetes or other sugar-related diseases, said method comprising the simultaneous evaluation and the combined interpretation of the percentage of glycated albumin (GA) and the levels 5 of methylglyoxal (MGO) in a biological sample obtained from a subject. The present invention relates furthermore to a method for determining the propensity for development of gestational diabetes, said method comprising the simultaneous evaluation and the combined interpretation of the percentage of glycated albumin (GA%) and the levels of 10 methylglyoxal (MGO) in a biological sample obtained from a subject in the 4th to 38th week of pregnancy.
2.WO/2021/009287BIOMARKERS FOR STROKE PROGNOSIS
WO - 21.01.2021
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/EP2020/070152 Applicant FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA Inventor MONTANER VILLALONGA, Joan
The application refers to an in vitro method for determining the prognosis in a patient suffering from stroke, the method comprising the step of determining the level of Alpha-1 antitrypsin (A1AT) in an isolated test sample obtained from the patient and deciding or recommending an appropriate medical regime accordingly. The application also provides for methods to identify stroke patients having a bad prognosis associated to high susceptibility to post-stroke infections.
3.WO/2021/010442PROTEIN AND RNA INTERACTION EVALUATION METHOD, INTERACTION MODULATOR EVALUATION METHOD AND INTERACTION MODULATOR DETECTION METHOD, AND FUSION PROTEIN, KIT AND BIOSENSOR USING SAME
WO - 21.01.2021
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/JP2020/027710 Applicant THE UNIVERSITY OF TOKYO Inventor ENDO Kei
Provided is a method for evaluating the interaction of a protein and RNA, said method comprising: (1) a step for bringing the following (a), (b), and (c) into contact in cytoplasm or a cell-free system, in which (a) is a first fusion protein obtained by fusing a subject protein and a first element of a marker protein, (b) is a second fusion protein obtained by fusing an RNA binding protein and a second element of the marker protein, and (c) is a ribonucleoprotein comprising fusion RNA which is obtained by fusing a subject RNA and RNA which forms a composite with the RNA binding protein; (2) a step for detecting a signal caused by the marker protein, which expresses a function by means of the first element and the second element being in close proximity; and (3) a step for determining the interaction of the subject protein and the subject RNA by means of detecting the signal, wherein if the subject protein and the subject RNA interacted, the first fusion protein and the ribonucleoprotein form a composite, and the marker protein function is expressed by means of the first element and the second element being in close proximity.
4.WO/2021/010712ANTI-TAU ANTIBODY AND USE OF SAME
WO - 21.01.2021
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
 Appl.No PCT/KR2020/009207 Applicant ADEL, INC. Inventor YOON, Seung-Yong
The present invention relates to an anti-tau antibody specifically binding to a tau protein, and a use of same. The anti-tau antibody according to the present invention specifically binds to a tau protein in which lysine at position 280 is acetylated and can suppress abnormal aggregation of tau proteins. In addition, the anti-tau antibody according to the present invention, when administered to an animal model of induced dementia, can improve locomotor activity and cognitive ability in the animal model. Therefore, the anti-tau antibody according to the present invention may be utilized in the prevention or treatment of neurodegenerative diseases.
5.WO/2021/010817APPARATUS TO MEASURE RIPENESS OF OIL PALM FRUITLETS VIA REAL-TIME CHLOROPHYLL CONTENT MEASUREMENT
WO - 21.01.2021
Int.Class G01N 21/64
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63optically excited
64Fluorescence; Phosphorescence
 Appl.No PCT/MY2020/000007 Applicant SIME DARBY PLANTATION INTELLECTUAL PROPERTY SDN. BHD. Inventor TEH, Huey Fang
An apparatus to measure ripeness of oil palm fruitlets via real-time chlorophyll content measurement of plurality of samples, the apparatus including an external housing (1), an optical window (3) connected to a flange (2), at least one probe holder (5) attached to the flange (2) to connect at least one fibre probe (4) to the flange (2) and optical window (3) to deliver excitation light from a plurality of light sources (9), a spectrometer (6) to analyse and measure light signals from the excited chlorophyll molecules in the plurality of samples based on different wavelengths, an array of detectors as contained in the spectrometer (6) to convert the light signals into electrical signals and a wireless network (8) and an application software as a data acquisition interface for real-time monitoring and to store the data in plurality of storage devices such as storage of electronic devices, portable mobile devices, cloud computing network or any combination thereof.
6.WO/2021/011417CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
WO - 21.01.2021
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
 Appl.No PCT/US2020/041710 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor CRAIK, Charles S.
The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.
7.WO/2021/011356SYSTEMS AND METHODS FOR EVALUATING IMMUNE RESPONSE TO INFECTION
WO - 21.01.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/US2020/041548 Applicant BECKMAN COULTER, INC. Inventor TEJIDOR, Liliana
Systems and methods for characterizing immune response to infection using cellular analysis, such as a hematological cellular analyzer. In some instances, the immune response may be characterized as normal or abnormal based on one or more blood cell population parameters. In some instances, abnormal characterization may be used to identify patients with sepsis or at elevated risk of developing sepsis.
8.WO/2021/009682COMPOSITIONS AND METHODS FOR ISOLATING, DETECTING, AND ANALYZING FETAL CELLS
WO - 21.01.2021
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No PCT/IB2020/056632 Applicant MENARINI BIOMARKERS SINGAPORE PTE LTD Inventor CASTAGNOLI, Paola
Compositions, kits, and methods for isolating, detecting, and analyzing fetal cells are provided. Methods for preparing a fetal cell sample and for performing fetal genetic testing are also provided herein. The compositions, kits, and methods may comprise or use an anti-TREML2 antibody. Alternatively, or additionally, the compositions, kits, and methods comprise or use an antibody conjugated to a colloidal magnetic particle and/or an exogenous aggregation enhancing factor.
9.WO/2021/010462METHOD AND TEST KIT FOR ASSISTING DIAGNOSIS OF BEHÇET'S DISEASE
WO - 21.01.2021
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/JP2020/027817 Applicant SCHOOL JURIDICAL PERSON HIGASHI-NIPPON GAKUEN Inventor NAGASAWA Toshiyuki
The present invention pertains to: a method for assisting the diagnosis of Behçet's disease, the method comprising a step for detecting an antibody that recognizes an amino acid sequence represented by SEQ ID NO: 1 in a sample collected from a test subject; and a test kit for an antibody that recognizes the amino acid sequence represented by SEQ ID NO: 1, the kit including a molecule that includes the amino acid sequence represented by SEQ ID NO: 1 as an epitope and a carrier for forming a solid phase including said molecule. The present invention enables provision of useful information contributing to the diagnosis of Behçet's disease.
10.WO/2021/007671URINALYSIS TEST STRIP FOR OVER-THE-COUNTER USE
WO - 21.01.2021
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/CA2020/050985 Applicant YOUCOUNT INC. Inventor DECHEV, Teodora
A test strip for urinalysis is provided, the test strip including a reagent pad for detecting a concentration of a selected analyte, the reagent pad attached to the test strip and comprising a substrate and an analyte detection system retained thereon, the analyte detection system including a plurality of components necessary for detection of the selected analyte, wherein at least one of the plurality of components is a variable component, the variable component immobilized on the substrate at a plurality of amounts on the reagent pad.
# -